In The News: March 2013

0
The U.S. Food and Drug Administration approved a drug by the name of Xeljanz (tofacitinib) as an alternative to methotrexate for the severe pain caused by rheumatoid arthritis (RA).
To continue reading this article or issue you must be a paid subscriber

Subscribe to Arthritis Advisor

Get the next year of Arthritis Advisor for just $20. And access all of our online content - over 1,000 articles - free of charge.
Subscribe today and save 36%. It's like getting 4 months FREE!
Already Subscribed?
| |

LEAVE A REPLY

Please enter your comment!
Please enter your name here